Plus Therapeutics (NASDAQ: PSTV) announced positive data from the ReSPECT-LM Phase 1 single dose escalation clinical trial, presented at the podium during the Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference.
Key Findings from the ReSPECT-LM Trial
The Phase 1 data demonstrated that treatment of leptomeningeal metastases (LM) with REYOBIQ™ is:
-
Feasible: The novel approach successfully delivered therapy directly to the cerebrospinal fluid.
-
Manageable in Safety: The safety profile supports continued development.
-
Promising in Efficacy: Early signals indicate potential benefit for patients with LM, a cancer complication with very limited treatment options.
Why This Matters
Leptomeningeal metastases (LM) are a devastating complication of advanced cancers, with few effective therapies currently available. The ReSPECT-LM trial represents one of the most advanced efforts to bring innovative radiotherapeutics into LM treatment, aiming to improve outcomes and provide new hope for patients and families.
Learn More
Read the full press release here.
Learn more about the ReSPECT-LM clinical trial here.
Commitment to CNS Cancer Innovation
At Plus Therapeutics, we remain dedicated to advancing radiotherapeutics for rare and difficult-to-treat central nervous system cancers, including leptomeningeal metastases. The encouraging results from the Phase 1 ReSPECT-LM trial further validate our mission to develop therapies that are safe, effective, and patient-centered.
#PlusTherapeutics #ReSPECTLM #REYOBIQ #LeptomeningealMetastases #LM #CNSMetastases #NeuroOncology #BrainCancer #Radiotherapeutics #CancerResearch #ClinicalTrials #PSTV #ASCO #SNO #SNOASCO2025
Recent Comments